Skip to main content

Optimize Your Biotech Spend—schedule your free consultation with a procurement expert to uncover cost-saving opportunities.

Talk to an Expert

View Our On-Demand Webinar

Engineered NK Cells:
The Next Frontier in Cancer Immunotherapy

This on-demand webinar, in partnership with OriGene, gives a look at the next frontier in cancer immunotherapy: engineered natural killer (NK) cells.  Explore cutting-edge advancements in CAR NK cell therapy and learn how genetic engineering and cytokine support are enhancing NK cell efficacy, leading to superior tumor control and prolonged survival in preclinical models. 

 

 

Prendio-BioProcure Logo   OriGene Logo Taglines

 

Watch the webinar now!

Featured Speaker:

Dr. Sunil Acharya, PhD

Sunil Acharya, PhD, is a graduate of the MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, where he earned his doctoral degree in cancer biology. Currently serving as a Principal Research Scientist in the laboratory of Dr. Katy Rezvani at MD Anderson Cancer Center, his primary research focus lies in advancing cellular therapy, particularly exploring the potential of Natural Killer (NK) cells as therapeutic agents. He leads the preclinical studies of CD70 CAR NK project which has progressed to a Phase I/II clinical trial targeting both hematologic and solid cancers.

Acharya_S_headshot
The Next Frontier in Cancer Immunotherapy

CAR NK cell therapy is redefining the landscape of cancer treatment. Unlike traditional T cell therapies, NK cells offer an off-the-shelf solution with no risk of graft-versus-host disease (GvHD), making them a promising allogeneic option. This webinar will explore how genetic engineering and cytokine support are enhancing NK cell efficacy, paving the way for more accessible and effective immunotherapies.

CD70 CAR NK Cells: A Game-Changer

Focusing on CD70 CAR NK cells, this session will highlight innovative strategies to optimize NK cell function. Learn how researchers are leveraging retroviral engineering and rigorous screening processes to develop potent tumor-targeting constructs. With promising preclinical results, CD70 CAR NK cells are now advancing into clinical trials, offering new hope for patients with hematologic malignancies and solid tumors.

What’s Next in Cell Therapy?

With Phase I/II trials underway, CAR NK therapy is moving closer to clinical reality. This webinar will provide key insights into the latest developments, challenges, and future directions of NK-based immunotherapies. Join us to gain expert perspectives on how engineered NK cells could revolutionize cancer treatment and expand access to life-saving therapies.